PARAGANGLIOMA
Clinical trials for PARAGANGLIOMA explained in plain language.
Never miss a new study
Get alerted when new PARAGANGLIOMA trials appear
Sign up with your email to follow new studies for PARAGANGLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cancer drug tested in rare tumors, but trial stopped early
Disease control TerminatedThis phase 2 trial tested the drug guadecitabine (SGI-110) in people aged 12 and older with rare cancers like wild-type GIST, pheochromocytoma, paraganglioma, and HLRCC-related kidney cancer that had not responded to other treatments. Participants received daily injections for 5 …
Matched conditions: PARAGANGLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental vaccine combo for rare adrenal cancers shows early promise but trial halted
Disease control TerminatedThis early-phase trial tested a new therapeutic vaccine (EO2401) combined with the immunotherapy drug nivolumab in 70 people with advanced adrenocortical carcinoma or malignant pheochromocytoma/paraganglioma. The goal was to see if the combination is safe and can shrink tumors or…
Matched conditions: PARAGANGLIOMA
Phase: PHASE1, PHASE2 • Sponsor: Enterome • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC